ArticleOncotarget2018

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF

Antoneicka L Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.